Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Prostate Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 56 articles: HTML format

Single Articles

March 2026
1. TURNHAM DJ, French R, Frame FM, Meniel VS, et al
   Inhibition of c-FLIP alongside TRAIL treatment suppresses prostate cancer stem cell activity.
   Br J Cancer. 2026 Mar 3. doi: 10.1038/s41416-026-03359.
   PubMed     Abstract available
   
   
   
2. DIXON KM, Lui GYL, Kovacevic Z, Zhang D, et al
   Correction to: Dp44mT targets the AKT, TGF-beta and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells.
   Br J Cancer. 2026 Mar 2. doi: 10.1038/s41416-026-03353.
   PubMed    
   
   
   
3. YANG J, Ryniawec JM, de Oliveira Pessoa D, Coope MR, et al
   Transient centrosome loss in cultured prostate epithelial cells induces chromosomal instability to produce an oncogenic genotype that correlates with poor clinical outcomes.
   Br J Cancer. 2026;134:924-938.
   PubMed     Abstract available
   
   
   January 2026
4. FULLER H, Agasaro OP, Guevara JM, Darst BF, et al
   Pre-diagnostic circulating untargeted metabolomics and risk of overall and clinically significant prostate cancer: a systematic review and meta-analysis.
   Br J Cancer. 2026 Jan 10. doi: 10.1038/s41416-025-03312.
   PubMed     Abstract available
   
   
   
5. VLACHOS G, Moser T, Lazzeri I, Moser MJ, et al
   Functional footprints of homologous recombination deficiency in prostate cancer revealed by ctDNA fragmentation and transcription factor accessibility.
   Br J Cancer. 2026 Jan 9. doi: 10.1038/s41416-025-03301.
   PubMed     Abstract available
   
   
   December 2025
6. NAIR-SHALLIKER V, Smith DP, Gebski V, Patel MI, et al
   High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD).
   Br J Cancer. 2025 Dec 21. doi: 10.1038/s41416-025-03278.
   PubMed     Abstract available
   
   
   
7. LIN R, Un H, Kang Y, Lei J, et al
   Senescence-related gene signature predicts prostate cancer progression and identifies PCNA as a therapeutic target via multi-omics machine learning integration.
   Br J Cancer. 2025 Dec 18. doi: 10.1038/s41416-025-03309.
   PubMed     Abstract available
   
   
   
8. WIDDING JL, Stroomberg HV, Dalton SO, Brasso K, et al
   The association between lower urinary tract symptoms and urinary tract infections, and subsequent prostate cancer workup: a nationwide population-based case-control study.
   Br J Cancer. 2025 Dec 3. doi: 10.1038/s41416-025-03288.
   PubMed     Abstract available
   
   
   November 2025
9. ZHU Y, Zarean E, Li DL, O'Reilly RL, et al
   Tumour-based epigenetic signatures as markers of prostate cancer aggressiveness after radical prostatectomy.
   Br J Cancer. 2025 Nov 20. doi: 10.1038/s41416-025-03257.
   PubMed     Abstract available
   
   
   
10. QIU C, Wang X, Francia G, Casiano CA, et al
    A panel of four autoantibodies to tumour-associated antigens in patients with prostate cancer and its potential for multi-cancer detection.
    Br J Cancer. 2025 Nov 18. doi: 10.1038/s41416-025-03242.
    PubMed     Abstract available
    
    
    
11. ZUCKER K, McInerney C, Glaser A, Baxter P, et al
    Why NHS hospital co-morbidity research may be wrong: how clinical coding fails to identify the impact of diabetes mellitus on cancer survival.
    Br J Cancer. 2025;133:1137-1144.
    PubMed     Abstract available
    
    
    October 2025
12. KLOOTS ISH, Slootbeek PHJ, Tolmeijer SH, van Wilpe S, et al
    Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study.
    Br J Cancer. 2025 Oct 31. doi: 10.1038/s41416-025-03243.
    PubMed     Abstract available
    
    
    
13. NIKHIL K, Haymour HS, Kamra M, Shah K, et al
    Correction: Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer.
    Br J Cancer. 2025 Oct 9. doi: 10.1038/s41416-025-03212.
    PubMed    
    
    
    
14. CHANG YH, Bresnahan ST, Taylor Head S, Harrison TA, et al
    Isoform-level analyses of 6 cancers uncover extensive genetic risk mechanisms undetected at the gene-level.
    Br J Cancer. 2025;133:874-885.
    PubMed     Abstract available
    
    
    September 2025
15. MAY M, Gilfrich C, Enzinger B, Brookman-May S, et al
    Exercise oncology in prostate cancer: from observational insight to prescriptive precision.
    Br J Cancer. 2025 Sep 16. doi: 10.1038/s41416-025-03205.
    PubMed    
    
    
    
16. HUANG H, Benzonana LL, Zhao H, Watts HR, et al
    Correction to: Prostate cancer cell malignancy via modulation of HIF-1alpha pathway with isoflurane and propofol alone and in combination.
    Br J Cancer. 2025 Sep 5. doi: 10.1038/s41416-025-03175.
    PubMed    
    
    
    July 2025
17. AN KY, Jeon JY, Arthuso FZ, Wang Q, et al
    Postdiagnosis physical activity is associated with improved survival in prostate cancer patients treated with surgery but not with radiation therapy.
    Br J Cancer. 2025 Jul 23. doi: 10.1038/s41416-025-03123.
    PubMed     Abstract available
    
    
    
18. FLAHERTY RL, Falcinelli M, Hesketh AR, Patel BA, et al
    Biomarkers of psychological stress are associated with increased susceptibility to the development of breast and prostate cancer in BRCA1/2 mutation carriers.
    Br J Cancer. 2025 Jul 2. doi: 10.1038/s41416-025-03085.
    PubMed     Abstract available
    
    
    April 2025
19. LI X, Mamouni K, Zhao R, Bai L, et al
    Novel Skp1 inhibitor has potent preclinical efficacy against castration-resistant prostate cancer.
    Br J Cancer. 2025 Apr 19. doi: 10.1038/s41416-025-02993.
    PubMed     Abstract available
    
    
    
20. HARTLEY A, Galbraith LCA, Shaw R, Tibbo A, et al
    Loss of ARID1A accelerates prostate tumourigenesis with a proliferative collagen-poor phenotype through co-operation with AP1 subunit cFos.
    Br J Cancer. 2025;132:502-512.
    PubMed     Abstract available
    
    
    March 2025
21. LI GX, Ma B, Zhang S, Liu R, et al
    EphB4-ephrin-B2 are targets in castration resistant prostate cancer.
    Br J Cancer. 2025 Mar 5. doi: 10.1038/s41416-025-02942.
    PubMed     Abstract available
    
    
    
22. O'SULLIVAN JM, Heinrich D, Castro E, George S, et al
    Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study.
    Br J Cancer. 2025;132:354-360.
    PubMed     Abstract available
    
    
    February 2025
23. LIN SC, Cheng YS, Lin YS, Nguyen TMH, et al
    The long noncoding RNA lncZBTB10 facilitates AR function via S-palmitoylation to promote prostate cancer progression and abiraterone resistance.
    Br J Cancer. 2025 Feb 16. doi: 10.1038/s41416-025-02938.
    PubMed     Abstract available
    
    
    
24. VAN DER KLEIJ MBA, Meertens M, Groenland SL, Kordes S, et al
    Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients.
    Br J Cancer. 2025 Feb 11. doi: 10.1038/s41416-025-02954.
    PubMed     Abstract available
    
    
    
25. WANG R, Wang S, Mi Y, Huang T, et al
    Elevated serum levels of GPX4, NDUFS4, PRDX5, and TXNRD2 as predictive biomarkers for castration resistance in prostate cancer patients: an exploratory study.
    Br J Cancer. 2025 Feb 3. doi: 10.1038/s41416-025-02947.
    PubMed     Abstract available
    
    
    December 2024
26. LUO L, Wang R, Bai L, Shang J, et al
    The accuracy of fluorine 18-labelled prostate-specific membrane antigen PET/CT and MRI for diagnosis of prostate cancer in PSA grey zone.
    Br J Cancer. 2024 Dec 19. doi: 10.1038/s41416-024-02934.
    PubMed     Abstract available
    
    
    
27. LIU C, Reger M, Fan H, Wang J, et al
    Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2024 Dec 16. doi: 10.1038/s41416-024-02929.
    PubMed     Abstract available
    
    
    
28. CHEN M, Zhou S, He X, Wen H, et al
    Identification of diagnostic biomarkers in prostate cancer-related fatigue by construction of predictive models and experimental validation.
    Br J Cancer. 2024 Dec 15. doi: 10.1038/s41416-024-02922.
    PubMed     Abstract available
    
    
    October 2024
29. RAHMAN R, Rahaman MH, Hanson AR, Choo N, et al
    Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.
    Br J Cancer. 2024 Oct 24. doi: 10.1038/s41416-024-02862.
    PubMed    
    
    
    
30. SHEN M, Garcia-Marques F, Muruganantham A, Liu S, et al
    Identification of a 5-gene signature panel for the prediction of prostate cancer progression.
    Br J Cancer. 2024 Oct 14. doi: 10.1038/s41416-024-02854.
    PubMed     Abstract available
    
    
    September 2024
31. CHOW ST, Fan J, Zhang X, Wang Y, et al
    Nuclear receptor TLX functions to promote cancer stemness and EMT in prostate cancer via its direct transactivation of CD44 and stem cell-regulatory transcription factors.
    Br J Cancer. 2024 Sep 26. doi: 10.1038/s41416-024-02843.
    PubMed     Abstract available
    
    
    
32. WANG T, Wang X, Ding G, Liu H, et al
    Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis.
    Br J Cancer. 2024 Sep 2. doi: 10.1038/s41416-024-02823.
    PubMed     Abstract available
    
    
    August 2024
33. NTURUBIKA BD, Guardia CM, Gershlick DC, Logan JM, et al
    Altered expression of vesicular trafficking machinery in prostate cancer affects lysosomal dynamics and provides insight into the underlying biology and disease progression.
    Br J Cancer. 2024 Aug 31. doi: 10.1038/s41416-024-02829.
    PubMed     Abstract available
    
    
    
34. RAHMAN R, Rahaman MH, Hanson AR, Choo N, et al
    CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.
    Br J Cancer. 2024 Aug 8. doi: 10.1038/s41416-024-02810.
    PubMed     Abstract available
    
    
    July 2024
35. LIN BB, Huang Q, Yan B, Liu M, et al
    An 18-gene signature of recurrence-associated endothelial cells predicts tumor progression and castration resistance in prostate cancer.
    Br J Cancer. 2024 Jul 12. doi: 10.1038/s41416-024-02761.
    PubMed     Abstract available
    
    
    
36. PUJANA-VAQUERIZO M, Bozal-Basterra L, Carracedo A
    Metabolic adaptations in prostate cancer.
    Br J Cancer. 2024 Jul 5. doi: 10.1038/s41416-024-02762.
    PubMed     Abstract available
    
    
    
37. CYLL K, Skaaheim Haug E, Pradhan M, Vlatkovic L, et al
    DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance.
    Br J Cancer. 2024 Jul 3. doi: 10.1038/s41416-024-02780.
    PubMed     Abstract available
    
    
    June 2024
38. ARMAKOLAS A, Alevizopoulos N, Stathaki M, Petraki C, et al
    Anti-PEc: Development of a novel monoclonal antibody against prostate cancer.
    Br J Cancer. 2024 Jun 20. doi: 10.1038/s41416-024-02713.
    PubMed     Abstract available
    
    
    March 2024
39. ZHANG Y, Stopsack KH, Wu K, Song M, et al
    Multivitamin use after diagnosis and prostate cancer survival among men with nonmetastatic prostate cancer.
    Br J Cancer. 2024 Mar 15. doi: 10.1038/s41416-024-02651.
    PubMed     Abstract available
    
    
    
40. GNANAPRAGASAM V
    Shifting the paradigm in the management of early prostate cancer.
    Br J Cancer. 2024 Mar 6. doi: 10.1038/s41416-024-02641.
    PubMed     Abstract available
    
    
    February 2024
41. EBERLEIN C, Williamson SC, Hopcroft L, Ros S, et al
    Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
    Br J Cancer. 2024 Feb 23. doi: 10.1038/s41416-024-02614.
    PubMed     Abstract available
    
    
    
42. LIU Q, Zhang Y, Vaselkiv JB, Mucci LA, et al
    A prospective study of birth weight and prostate cancer risk and mortality in the Health Professionals Follow-up Study.
    Br J Cancer. 2024 Feb 22. doi: 10.1038/s41416-024-02593.
    PubMed     Abstract available
    
    
    
43. CONSTANTIN TA, Varela-Carver A, Greenland KK, de Almeida GS, et al
    Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
    Br J Cancer. 2024 Feb 14. doi: 10.1038/s41416-024-02606.
    PubMed    
    
    
    
44. O'MALLEY DE, Raspin K, Melton PE, Burdon KP, et al
    Acquired copy number variation in prostate tumours: a review of common somatic copy number alterations, how they are formed and their clinical utility.
    Br J Cancer. 2024;130:347-357.
    PubMed     Abstract available
    
    
    January 2024
45. MAH CY, Nguyen ADT, Niijima T, Helm M, et al
    Peroxisomal beta-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer.
    Br J Cancer. 2024 Jan 12. doi: 10.1038/s41416-023-02557.
    PubMed     Abstract available
    
    
    December 2023
46. FRITZ J, Jochems SHJ, Bjorge T, Wood AM, et al
    Body mass index, triglyceride-glucose index, and prostate cancer death: a mediation analysis in eight European cohorts.
    Br J Cancer. 2023 Dec 12. doi: 10.1038/s41416-023-02526.
    PubMed     Abstract available
    
    
    November 2023
47. ZHAO JL, Antonarakis ES, Cheng HH, George DJ, et al
    Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
    Br J Cancer. 2023 Nov 18. doi: 10.1038/s41416-023-02487.
    PubMed     Abstract available
    
    
    
48. SHEN J, Chowdhury S, Agarwal N, Karsh LI, et al
    Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
    Br J Cancer. 2023 Nov 11. doi: 10.1038/s41416-023-02492.
    PubMed     Abstract available
    
    
    
49. AHMAD AS, Offman J, Delon C, North BV, et al
    Years of life lost due to cancer in the United Kingdom from 1988 to 2017.
    Br J Cancer. 2023;129:1558-1568.
    PubMed     Abstract available
    
    
    
50. CAMERON JM, Sala A, Antoniou G, Brennan PM, et al
    A spectroscopic liquid biopsy for the earlier detection of multiple cancer types.
    Br J Cancer. 2023;129:1658-1666.
    PubMed     Abstract available
    
    
    
51. SHEN M, Liu S, Toland A, Hsu EC, et al
    ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype.
    Br J Cancer. 2023;129:1818-1828.
    PubMed     Abstract available
    
    
    October 2023
52. FENG X, Zhang Y, Vaselkiv JB, Li R, et al
    Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy.
    Br J Cancer. 2023 Oct 28. doi: 10.1038/s41416-023-02472.
    PubMed     Abstract available
    
    
    
53. TURPIN A, Delliaux C, Parent P, Chevalier H, et al
    Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor.
    Br J Cancer. 2023 Oct 24. doi: 10.1038/s41416-023-02449.
    PubMed     Abstract available
    
    
    
54. GULLIVER C, Huss S, Semjonow A, Baillie GS, et al
    Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation and alterations in DNA repair: implications for therapeutic strategies.
    Br J Cancer. 2023;129:1462-1476.
    PubMed     Abstract available
    
    
    September 2023
55. HOU Y, Jiang KW, Wang LL, Zhi R, et al
    Biopsy-free AI-aided precision MRI assessment in prediction of prostate cancer biochemical recurrence.
    Br J Cancer. 2023 Sep 27. doi: 10.1038/s41416-023-02441.
    PubMed     Abstract available
    
    
    
56. HINNEH JA, Gillis JL, Mah CY, Irani S, et al
    Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer.
    Br J Cancer. 2023 Sep 6. doi: 10.1038/s41416-023-02406.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum